Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 295-304
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Figure 1 Kaplan–Meier curves of time of aflibercept treatment failure and median survival time post-aflibercept in the second-line and the salvage therapy settings.
A: Time to aflibercept treatment failure; B: Median survival time post-aflibercept. P values were calculated by the log-rank test. aTTF: Time to aflibercept treatment failure; aMST: Median survival time post-aflibercept.
- Citation: Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304
- URL: https://www.wjgnet.com/1948-5204/full/v13/i4/295.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i4.295